Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) EBITDA Margin: 2009-2020

Historic EBITDA Margin for Avadel Pharmaceuticals (AVDL) over the last 11 years, with Dec 2020 value amounting to 431.08%.

  • Avadel Pharmaceuticals' EBITDA Margin rose 49790.00% to 431.08% in Q4 2020 from the same period last year, while for Dec 2020 it was 36.88%, marking a year-over-year increase of 7760.00%. This contributed to the annual value of 26.04% for FY2020, which is 6676.00% up from last year.
  • Avadel Pharmaceuticals' EBITDA Margin amounted to 431.08% in Q4 2020, which was up 2.57% from 420.28% recorded in Q3 2020.
  • In the past 5 years, Avadel Pharmaceuticals' EBITDA Margin ranged from a high of 431.08% in Q4 2020 and a low of -360.52% during Q4 2018.
  • Moreover, its 3-year median value for EBITDA Margin was -33.53% (2018), whereas its average is 45.61%.
  • In the last 5 years, Avadel Pharmaceuticals' EBITDA Margin crashed by 509,125bps in 2016 and then spiked by 49,790bps in 2020.
  • Quarterly analysis of 5 years shows Avadel Pharmaceuticals' EBITDA Margin stood at 39.61% in 2016, then slumped by 5,135bps to -11.74% in 2017, then slumped by 34,878bps to -360.52% in 2018, then skyrocketed by 29,370bps to -66.82% in 2019, then surged by 49,790bps to 431.08% in 2020.
  • Its EBITDA Margin stands at 431.08% for Q4 2020, versus 420.28% for Q3 2020 and 399.06% for Q2 2020.